Al-Ola A Abdallah: Insights into bispecific T-cell engagers
Al-Ola A Abdallah, Associate Professor, Plasma Cell Disorder Program Director, Division of HMCT/University of Kansas Medical Center, posted the following on X:
“Bispecific Antibodies:
1) BiTEs (Bispecific T-cell Engagers): Comprise two scFvs, one targeting a tumor-associated antigen and the other targeting CD3 on T cells. A flexible linker connects the two domains, allowing for versatile interaction with the targets.
2) DARTs (Dual-Affinity Retargeting molecules): Have a diabody backbone with two polypeptide chains, where VH domains are connected by a disulfide bond. DARTs offer greater stability and potentially higher T-cell activation compared to BiTEs
3) BiKEs (Bispecific Killer Engagers): Heterodimeric bispecific scFvs that target NK cells.
4) TriKEs (Trispecific Killer Engagers): Include an IL-15 crosslinker for enhanced NK cell stimulation.
5) TandAbs (Tandem diabodies): Tetravalent molecules consisting of two linked diabodies, each having two binding sites for each antigen. They offer improved stabilization and longer half-life compared to smaller molecules due to their molecular weight.
”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023